🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are excited to present “SOM Biotech: Drug repurposing for Rare diseases” at the Open Innovation Madrid Norte Forum on science and technology today. For more information, click here: eventos.uam.es/74500/detail/c…

We have signed a letter of intent with Megapharm regarding a potential distribution agreement for the commercialization of SOM3355 to treat chorea symptoms in Huntington’s disease in Israel and the Palestinian Authority. Read more here: sombiotech.com/som-biotech-si…

Our Newsletter for Q4 of 2021 has been launched. Find it here lnkd.in/eJdpu2Pb You can subscribe to receive the latest updates on SOM Biotech via the newsletter, clicking the button "Subscribe" at the end of our webpage. We wish you a Merry Christmas and a Happy New Year!

We are excited to virtually attend this year’s BIO at J.P. Morgan and discuss our proprietary drug discovery platform SOMAIPRO. #JPM22 #healthcare #drugdiscovery bio.org/events/bio-par…

We are soon approaching #RareDiseaseDay 2022! Did you know that over 300 million people from around the world have a rare disease? Learn more and get involved at: rarediseaseday.org

Today is #RareDiseaseDay 2022! At SOM we recognize the importance of raising awareness and progressing scientific research in the field of #rarediseases. Join us and get involved today: rarediseaseday.org/#

#HuntingtonsDisease is a rare inherited neurodegenerative disorder of the central nervous system. Join us in supporting #RareDiseaseDay and raise awareness and generate change for those living with rare diseases, including Huntington’s. rarediseaseday.org

Phenylketonuria (PKU) occurs in an estimated 1 in 23,390 births globally. This #RareDiseaseDay, PKU sufferer, Michelle teamed up with @Eurordis to tell her story. Read here: rarediseaseday.org/heroes/pku-gir…

Currently approved treatments for #Huntington’s disease are associated with a number of severe side effects. That’s why #RareDiseaseDay is important, as we aim to encourage education and further research into Rare Diseases, to address these unmet needs. rarediseaseday.org

Yesterday our CEO, Raúl Insa participated, as a former winner of #EmprendedorXXI Awards, in the round table “Launching and scaling tech companies in Europe. A view from Spanish and Israeli founders” at Day One Innovation Summit Catalonia in the framework of #4YFN22.

We are attending this year’s BIO-Europe Spring Virtual Conference. We look forward to hearing from industry experts and holding discussions with new partners. To schedule a meeting with SOM Biotech, click here: informaconnect.com/bioeurope-spri… #BIOEurope22 #SOMBiotech

We are happy to attend Outsourcing in Clinical Trials Europe 2022 on the 4th and 5th of May in Barcelona. It is a great opportunity to learn about the latest innovations and insights. arena-international.com/octeurope/ #clinicaltrials #OCT

SOM Biotech will be presenting at the International #Duchenne Congress organized by Duchenne Parent Project España from the 13th to the 15th of May. The presentation will be dedicated to the repurposing strategies for this devastating muscle-wasting disease appearing in newborns. #CongresoDPPS22

Yesterday SOM Biotech participated in the poster session of the International Congress of Duchenne and Becker Spain (#CongresoDPPS22), organized by the Duchenne Parent Project España, and sponsored by #catedraUBenfermedadesraras of Universitat de Barcelona

We were happy to participate in the International Congress of Duchenne and Becker Spain. Thanks to Duchenne Parent Project España and Marisol Montolio for the excellent organization of the event, and to the sponsors #catedraUBenfermedadesraras, Universitat de Barcelona #CongresoDPPS22 #duchenne #drugdiscovery

SOM Biotech yesterday announced that it signed a licensing agreement with the University of Minnesota. You can find out more about this by following the link: lnkd.in/egbqis7H #drugdiscovery #licensing

Working with CaixaBank to find investors in the European market and close a €32M #seriesb round to continue advancing in the development of drugs for the treatment of #rarediseases. Article by expansioncom : bit.ly/3IbgYHX

14 days to go for #RareDiseaseDay! As researchers working to develop therapies for #RareDiseases, we’ll #LightUpForRare to raise #awareness and #support Rare Disease Day and 300 million people worldwide living with a rare disease. #ShareYourColours

It’s #RareDiseaseDay! Today and every day, awareness, support and research are essential. Most #RareDiseases are life threatening: there’s an urgent need to find new treatments. 💜💚💙 #LightUpForRare & #ShareYourColours #RareDiseaseDay2023 #LightUpForRare #ShareYourColours

On #RareDiseaseDay & every day, we leverage AI to repurpose drugs to treat #RareDiseases like TTR Amyloidosis, Phenylketonuria, Tardive Dyskinesia or Duchenne Muscular Dystrophy. ℹWe’re carrying out a Phase 2b clinical trial to treat Chorea in Huntington’s Disease. #CareForRare